Philip Morris International Inc
PM evidence brief
What we can confirm
- Market Cap:
- $302.39B
What it means
What to watch
Prepared research question
What matters most for PM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PM
Philip Morris International Inc (PM) is a multinational tobacco and nicotine company transitioning toward smoke-free products, with a focus on innovative nicotine pouches and reduced-risk products.
Key risk: Negative shareholders' equity
Market Cap
$302.39B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials for Philip Morris International Inc.
Philip Morris International Inc (PM) is a multinational tobacco and nicotine company transitioning toward smoke-free products, with a focus on innovative nicotine pouches and reduced-risk products.
- Cash & equivalents of $5,999.0M as of 2026-06-30 [sec]
- Total revenue of $11,192.0M as of 2026-06-30 [sec]
- Net income of $2,817.0M as of 2026-06-30 [sec]
- Shareholders' equity of -$8,583.0M as of 2026-06-30 [sec]
- Total debt of $45,707.0M as of 2026-06-30 [sec]
What works
- The company has a dedicated board committee reviewing R&D and innovation strategy for smoke-free products (SFPs) and wellness business, indicating structured oversight [sec · filed 2026-03-26]
- The US launch of Zyn Ultra nicotine pouches is viewed as a potential growth catalyst by analysts [news · published 2026-06-03]
What to weigh
- Shareholders' equity is negative at -$8,583.0M as of 2026-06-30, indicating liabilities exceed assets [sec]
- Total debt of $45,707.0M as of 2026-06-30 represents a significant financial obligation [sec]
From the filings
Quoted directly from source documents.
Company has a board committee overseeing smoke-free product innovation
“review and report to the Board the overall research and development and innovation strategy of the Company; • review the Company's pipeline of innovative products and services, including existing and future SFPs”
SEC filings · March 26, 2026
Risks & what to watch (2)›
Key risks
- Negative shareholders' equity — Shareholders' equity of -$8,583.0M as of 2026-06-30 indicates the company's liabilities exceed its assets [sec]
- High total debt burden — Total debt of $45,707.0M as of 2026-06-30 represents a substantial financial obligation [sec]
What to watch
- US market adoption of Zyn Ultra nicotine pouches following its launch [news · published 2026-06-03]
- Progress of the company's smoke-free product pipeline and innovation strategy as overseen by the board committee [sec · filed 2026-03-26]
Sources: Competitor trials · News · SEC filings · Generated October 7, 2026 · How we verify sources →
Run Philip Morris International Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Philip Morris International Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 1.1%
- Days to cover
- 3.4
- Shares short
- 16,281,118
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Philip Morris International Inc?
Philip Morris International Inc (PM) is a multinational tobacco and nicotine company transitioning toward smoke-free products, with a focus on innovative nicotine pouches and reduced-risk products.
Who is the CEO of Philip Morris International Inc?
Mr. Jacek Olczak is the chief executive officer of Philip Morris International Inc (PM).
Where is Philip Morris International Inc headquartered?
Philip Morris International Inc (PM) is headquartered in Stamford, CT, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.